Soho House, GoodRx Holdings, Dayforce, and Other Major Stocks Rising on Monday
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 18 2025
0mins
Should l Buy VOYG?
Source: Benzinga
U.S. Stock Market Performance: U.S. stocks mostly declined, with the Dow Jones index dropping approximately 0.1% on Monday.
Soho House Deal Announcement: Soho House & Co Inc shares surged 15.3% to $8.81 after announcing a $2.7 billion deal to go private, offering investors $9.00 per share in cash.
Notable Stock Gains: GoodRx Holdings saw a significant increase of 33.7% following a collaboration announcement, while other companies like Dayforce and Xunlei also recorded substantial gains.
Investment Opportunities: Various investment platforms and opportunities were highlighted, including options for buying shares in homes, trading global markets, and investing in AI-powered wealth management.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VOYG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VOYG
Wall Street analysts forecast VOYG stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 27.300
Low
25.00
Averages
38.80
High
45.00
Current: 27.300
Low
25.00
Averages
38.80
High
45.00
About VOYG
Voyager Technologies, Inc. is a defense technology and space solutions company. The Company is developing and delivering transformative, mission-critical solutions to customers, enabled by its advanced technology, analytics and space infrastructure capabilities. Its solutions include communications and intelligence collection systems, defense systems, advanced space technology, in-space infrastructure and space mission services. The Company’s business consists of diversified solutions across three business segments: Defense & National Security provides mission-critical solutions to protect dynamic and contested domains; Space Solutions delivers space infrastructure, advanced space technology, science systems and mission services that power commercial, academic and government missions from low-Earth orbit to deep space, and Starlab Space Stations, is a commercial space station planned to succeed the ISS and provide continued permanent human presence in space.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Starlab Partners with Helogen to Advance Space Biological Research
- Collaborative Innovation: Starlab Space's partnership with Helogen Corporation integrates the HEL-IOS™ biomedical operating system into the Starlab space station, facilitating a shift from isolated experiments to scalable biological discoveries in microgravity.
- Automated Production: HEL-IOS™ enables fully autonomous, regulatory-grade manufacturing of high-value biomaterials by integrating biological cultivation, processing, sequencing, and real-time analytics, thereby reducing reliance on crew intervention and enhancing production efficiency in space.
- Market-Driven Model: Starlab's business model aims to lower research costs and complexity, with a single-launch, no-assembly-required architecture that achieves full certification and operational readiness within weeks of launch, maximizing efficiency for payload customers.
- Scientific Breakthrough Potential: Research in microgravity conditions aids in improving protein crystallization, 3D cell growth, and disease model development, potentially leading to significant advancements in treating conditions such as Parkinson's disease, diabetes, and Alzheimer's disease.
See More
Helogen Partners with Starlab to Advance Space Biological Research
- Integration of Automated Biological Systems: Helogen's integration of its HEL-IOS™ system into the Starlab space station enables continuous autonomous biological discovery in low Earth orbit, marking a significant advancement in space biological research that is expected to enhance the efficiency and quality of biomaterial production.
- Production of High-Value Biomaterials: The HEL-IOS™ system creates a closed-loop process by integrating biological cultivation, processing, sequencing, and real-time analytics, allowing for automated production of high-value biomaterials without continuous crew intervention, thereby reducing operational costs and increasing production capacity.
- Advantages of Microgravity Research: The microgravity environment offers conditions that cannot be replicated on Earth, improving protein crystallization, 3D cell growth, and disease modeling, which is expected to accelerate drug development and research advancements for conditions like Alzheimer's disease.
- Market-Driven Business Model: Starlab's single-launch, no-assembly-required architecture enables full certification and operational readiness within weeks of launch, minimizing delays and maximizing efficiency, providing researchers and commercial partners with lower costs and reduced risks.
See More
Voyager Partners with ATMOS to Enhance Space Access
- Strategic Partnership: Voyager Technologies has signed a strategic partnership with ATMOS Space Cargo to enhance access to space for scientific discovery and technology advancement, reflecting a shared belief in simplifying customer access to space services.
- One-Stop Service Platform: Voyager will serve as ATMOS's integration and implementation partner, providing comprehensive mission management services that ensure seamless execution from Earth to space, thereby improving mission efficiency and success rates for clients.
- Microgravity Mission Support: ATMOS's free-flying PHOENIX vehicles will complement Voyager's mission management capabilities, supporting microgravity missions across the International Space Station and next-generation commercial platforms, enhancing market competitiveness and expanding the customer base.
- Global Integration Capability: Voyager Europe, as the European subsidiary, leverages its deep mission management experience and global integration capabilities to provide efficient space operation solutions for clients, driving the rapid advancement of microgravity missions and the return of results to Earth.
See More
Voyager Technologies Schedules Q4 2025 Earnings Call
- Earnings Call Schedule: Voyager Technologies will host its Q4 2025 earnings results conference call on March 10, 2026, at 9 a.m. ET, with senior management participating, indicating the company's commitment to transparency and investor communication as results will be published after market close on March 9, 2026.
- Live Webcast and Replay: The call will be available via live webcast on the Events & Presentations section of Voyager's investor relations website, with a replay accessible approximately one hour after the call, ensuring that investors who cannot attend live can still access critical information, enhancing investor engagement.
- Shareholder Q&A Session: Voyager is partnering with Robinhood's Say Technologies to enable verified retail and institutional shareholders to post and upvote questions starting February 23, 2026, with management responding to selected top-voted questions during the call, reflecting the company's emphasis on shareholder feedback.
- Company Mission and Vision: Voyager Technologies focuses on defense and space technology, committed to delivering transformative, mission-critical solutions aimed at tackling complex challenges, fortifying national security, and protecting critical assets, showcasing its strategic positioning and long-term growth potential in the industry.
See More
Starlab Partners with Auxilium to Advance Space Biomanufacturing
- Biomanufacturing Partnership: Starlab Space LLC has partnered with Auxilium Biotechnologies to provide 3D bioprinting and biofabrication capabilities aboard its commercial space station, significantly advancing research in regenerative medicine and implantable medical devices.
- Innovative Technology Application: Auxilium's AMP-1 3D bioprinter has successfully mass-produced complex structures aboard the International Space Station, and will accelerate the translation from experimental biology to manufacturable products at Starlab, enhancing production capabilities in life sciences.
- Microgravity Advantages: 3D printing in microgravity enables tissue architectures and material properties unattainable under standard gravity, facilitating breakthroughs in drug development, cell growth, and disease modeling, with significant clinical application potential.
- Market-Driven Model: Starlab's business model aims to reduce costs and complexities for researchers and commercial partners, ensuring rapid certification and operation through a single-launch, no-assembly-required design, thereby maximizing research efficiency and outcomes.
See More
Auxilium Partners with Starlab to Advance Space Bioprinting
- Space Bioprinting Capabilities: Auxilium will provide 3D bioprinting and biofabrication capabilities aboard the Starlab space station, aimed at enhancing R&D in regenerative medicine, implantable medical devices, and tissue engineering, marking a significant advancement in the field of space biomanufacturing.
- Microgravity Advantage: Auxilium's AMP-1 platform successfully created tiny functional blood vessels aboard the International Space Station in under an hour, an achievement not possible on Earth, which opens possibilities for supporting astronaut health during long missions to the Moon and Mars.
- Accelerating Product Translation: The collaboration with Starlab will accelerate the translation from experimental biology to manufacturable products, positioning AMP-1 as a production facility for the next generation of life science technologies in space, thereby advancing complex tissue engineering applications.
- Innovative Infrastructure: The infrastructure provided by Starlab will lower barriers for industry and academia, fostering high-impact research and manufacturing that will lead to breakthrough therapies, ultimately improving lives on Earth.
See More
Starlab Partners with Helogen to Advance Space Biological Research
- Collaborative Innovation: Starlab Space's partnership with Helogen Corporation integrates the HEL-IOS™ biomedical operating system into the Starlab space station, facilitating a shift from isolated experiments to scalable biological discoveries in microgravity.
- Automated Production: HEL-IOS™ enables fully autonomous, regulatory-grade manufacturing of high-value biomaterials by integrating biological cultivation, processing, sequencing, and real-time analytics, thereby reducing reliance on crew intervention and enhancing production efficiency in space.
- Market-Driven Model: Starlab's business model aims to lower research costs and complexity, with a single-launch, no-assembly-required architecture that achieves full certification and operational readiness within weeks of launch, maximizing efficiency for payload customers.
- Scientific Breakthrough Potential: Research in microgravity conditions aids in improving protein crystallization, 3D cell growth, and disease model development, potentially leading to significant advancements in treating conditions such as Parkinson's disease, diabetes, and Alzheimer's disease.
See More
Helogen Partners with Starlab to Advance Space Biological Research
- Integration of Automated Biological Systems: Helogen's integration of its HEL-IOS™ system into the Starlab space station enables continuous autonomous biological discovery in low Earth orbit, marking a significant advancement in space biological research that is expected to enhance the efficiency and quality of biomaterial production.
- Production of High-Value Biomaterials: The HEL-IOS™ system creates a closed-loop process by integrating biological cultivation, processing, sequencing, and real-time analytics, allowing for automated production of high-value biomaterials without continuous crew intervention, thereby reducing operational costs and increasing production capacity.
- Advantages of Microgravity Research: The microgravity environment offers conditions that cannot be replicated on Earth, improving protein crystallization, 3D cell growth, and disease modeling, which is expected to accelerate drug development and research advancements for conditions like Alzheimer's disease.
- Market-Driven Business Model: Starlab's single-launch, no-assembly-required architecture enables full certification and operational readiness within weeks of launch, minimizing delays and maximizing efficiency, providing researchers and commercial partners with lower costs and reduced risks.
See More
Voyager Partners with ATMOS to Enhance Space Access
- Strategic Partnership: Voyager Technologies has signed a strategic partnership with ATMOS Space Cargo to enhance access to space for scientific discovery and technology advancement, reflecting a shared belief in simplifying customer access to space services.
- One-Stop Service Platform: Voyager will serve as ATMOS's integration and implementation partner, providing comprehensive mission management services that ensure seamless execution from Earth to space, thereby improving mission efficiency and success rates for clients.
- Microgravity Mission Support: ATMOS's free-flying PHOENIX vehicles will complement Voyager's mission management capabilities, supporting microgravity missions across the International Space Station and next-generation commercial platforms, enhancing market competitiveness and expanding the customer base.
- Global Integration Capability: Voyager Europe, as the European subsidiary, leverages its deep mission management experience and global integration capabilities to provide efficient space operation solutions for clients, driving the rapid advancement of microgravity missions and the return of results to Earth.
See More
Voyager Technologies Schedules Q4 2025 Earnings Call
- Earnings Call Schedule: Voyager Technologies will host its Q4 2025 earnings results conference call on March 10, 2026, at 9 a.m. ET, with senior management participating, indicating the company's commitment to transparency and investor communication as results will be published after market close on March 9, 2026.
- Live Webcast and Replay: The call will be available via live webcast on the Events & Presentations section of Voyager's investor relations website, with a replay accessible approximately one hour after the call, ensuring that investors who cannot attend live can still access critical information, enhancing investor engagement.
- Shareholder Q&A Session: Voyager is partnering with Robinhood's Say Technologies to enable verified retail and institutional shareholders to post and upvote questions starting February 23, 2026, with management responding to selected top-voted questions during the call, reflecting the company's emphasis on shareholder feedback.
- Company Mission and Vision: Voyager Technologies focuses on defense and space technology, committed to delivering transformative, mission-critical solutions aimed at tackling complex challenges, fortifying national security, and protecting critical assets, showcasing its strategic positioning and long-term growth potential in the industry.
See More
Starlab Partners with Auxilium to Advance Space Biomanufacturing
- Biomanufacturing Partnership: Starlab Space LLC has partnered with Auxilium Biotechnologies to provide 3D bioprinting and biofabrication capabilities aboard its commercial space station, significantly advancing research in regenerative medicine and implantable medical devices.
- Innovative Technology Application: Auxilium's AMP-1 3D bioprinter has successfully mass-produced complex structures aboard the International Space Station, and will accelerate the translation from experimental biology to manufacturable products at Starlab, enhancing production capabilities in life sciences.
- Microgravity Advantages: 3D printing in microgravity enables tissue architectures and material properties unattainable under standard gravity, facilitating breakthroughs in drug development, cell growth, and disease modeling, with significant clinical application potential.
- Market-Driven Model: Starlab's business model aims to reduce costs and complexities for researchers and commercial partners, ensuring rapid certification and operation through a single-launch, no-assembly-required design, thereby maximizing research efficiency and outcomes.
See More
Auxilium Partners with Starlab to Advance Space Bioprinting
- Space Bioprinting Capabilities: Auxilium will provide 3D bioprinting and biofabrication capabilities aboard the Starlab space station, aimed at enhancing R&D in regenerative medicine, implantable medical devices, and tissue engineering, marking a significant advancement in the field of space biomanufacturing.
- Microgravity Advantage: Auxilium's AMP-1 platform successfully created tiny functional blood vessels aboard the International Space Station in under an hour, an achievement not possible on Earth, which opens possibilities for supporting astronaut health during long missions to the Moon and Mars.
- Accelerating Product Translation: The collaboration with Starlab will accelerate the translation from experimental biology to manufacturable products, positioning AMP-1 as a production facility for the next generation of life science technologies in space, thereby advancing complex tissue engineering applications.
- Innovative Infrastructure: The infrastructure provided by Starlab will lower barriers for industry and academia, fostering high-impact research and manufacturing that will lead to breakthrough therapies, ultimately improving lives on Earth.
See More
